Let’s make every year the “Year of the Dog”

1. Let’s make every year the “Year of the Dog” 2018

2. The Cancer Challenge We have not solved the Cancer problem yet! • Prevention strategies are limited • Many cancer types remain refractory to therapy • While cancer outcomes are improving (for many, but not all cancers), short-term and long-term toxicities from current cancer therapies (surgery, radiation, chemo) are quite significant, including cardiovascular disease, metabolic disorders, and organ dysfunction (kidney, liver, heart, etc).

3. Cancer is a Challenge • Cancer is common in humans and canines • ~1 of every 3 women, ~1 of every 2 men will develop cancer • ~1.7 million Americans will be diagnosed with cancer this year • >600 thousand Americans will die from cancer this year • {9/11 two hundred times each year!} • >4 million canines will develop cancer in U.S.; >1 million will receive treatment for their cancer. • ~50% of canines >10yo will die from cancer

4. Cancer Remains a Challenge • There remains a great need for new cancer therapies – better efficacy, less toxicity • The process of developing new cancer therapies is both slow and costly: • Average of 13-16 years to bring a new therapeutic from target validation to marketplace • <<10% of new drugs developed make it to the marketplace • ~$1.8 billion to bring a new drug to market

5. The Cancer Opportunity • Consortium for • Canine Comparative Oncology • A partnership: • Collaborate in pre-clinical and clinical research activities • Advance understanding of cancer causation • Identify cancer susceptibility genes • Identify environmental factors involved in cancer • Test novel agents • Pre-clinical testing • Coordinate clinical trials in canines and humans • Joint partnerships with Pharma/Biotech • PK/PD, biomarkers, dosing/scheduling, combinations

6. The Cancer Opportunity • Who will benefit? • Human patients • Canine patients • Canine owners • New insights into cancer biology • Faster, less costly drug approvals? • Better informed clinical trials design

7. The Cancer Opportunity This would be an iterative process Canine Clinical Trials Human Clinical Trials Cancer Drug Approval

8. C30 Pilot Projects – 2018-2019 2018 Pilot Project Awardee Presentations Establishing Laser Ablation as a Treatment for Canine Glioma and Modeling the Human Condition Peter Fecci, MD, PhD and Christopher Mariani, DVM, PhD Phase 2 of the MDH Pipeline – Bortezomib as a First Line Therapy for Osteosarcoma William Eward, MD, DVM and Steven Suter, DVM, PhD Testing a New Prodrug Nanoparticle Formulation of Niclosamide as a Novel Therapy for Osteosarcoma William Eward, MD, DVM and Steven Suter, DVM, PhD A Continued Phase I Clinical Trial of CP-DOX in Dogs Ashutosh Chilkoti, PhD and Steven Suter, DVM, PhD

9. 4th Annual C30 Symposium 8:15-9:45AM 2018 Pilot Project Awardee Presentations 9:45-10:05AM CORC Presentation Susan Braun, V Foundation; Wendy Shelton 10:05-11:00AM 2019 Poster Awardee Presentations 11:00AM-12:15PM Lunch & Poster Session 12:15-12:45PM Amy LeBlanc, DVM – The NCI-COP Perspective 12:45-1:00PM Toby Hecht, PhD – NCI Canine Data Commons 1:00-1:30PM Tanja Zabka, DVM, DACVP, Genentech (Pharma perspective) 2:00-2:45PM Industry Panel Discussion 2:45-3:34PM Keynote Address Elizabeth McNiel, DVM, PhD (Elanco Animal Health) Pharma Partnerships – Human and animal health

10. Let’s make every year the ’Year of the Dog”